Biotech Values : SNY acquires PRVB for $25.00 cash

Biotech Values

Replies (2) Next 10 Prev Next

Send PM Follow Ignore

Re: DewDiligence post# 244558

Monday, 03/13/2023 11:21:44 AM

Monday, March 13, 2023 11:21:44 AM

SNY acquires PRVB for $25.00 cash—a 273%(!) premium to Friday’s closing price:

https://finance.yahoo.com/news/press-release-sanofi-acquire-provention-060000049.html

The nominal deal value is $2.9B.

SNY and PRVB already had a US co-marketing deal for Tzield, PRVB’s novel drug to delay the onset of T1D (#msg-170131014).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Keep Last Read

Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.